FDA Brief

Warning letters Drugs

FDA warning letter to

Seatex, LLC

High riskIssued Apr 1, 2024Posted May 21, 2024Division of Pharmaceutical Quality Operations II

FDA: Seatex made hand sanitizer on equipment also used for floor cleaner and skipped ingredient identity tests.

What happened

FDA inspected Seatex's drug manufacturing facility in Rosenberg, Texas, from October 16 to October 20, 2023. Investigators found the company made over-the-counter hand sanitizer on equipment shared with non-drug products such as industrial floor cleaner, without cleaning validation, and found failing test results were retested away rather than investigated. Seatex recalled four products nationwide on February 19, 2024, and said it stopped making drugs at the site.

What FDA found

  1. The company had no adequate written procedures for cleaning and maintaining equipment, and no cleaning validation studies to show the cleaning worked.

    21 CFR 211.67(b)
  2. The company made drugs on the same equipment used for industrial chemicals like floor cleaner, which FDA called unacceptable because of cross-contamination risk.

    21 CFR 211.67(b)
  3. The company did not properly investigate out-of-specification test results; it retested a new sample until a passing result came back, and did not record or keep the failing results.

    21 CFR 211.192
  4. The company did not run at least one identity test on each incoming shipment of components such as ethanol and glycerin before use.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. Specifications for ethanol did not test for methanol, and specifications for glycerin did not include the USP limit test for diethylene glycol (DEG) or ethylene glycol (EG), both of which have caused fatal poisonings.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  6. The company relied on supplier certificates of analysis without qualifying the suppliers, and had no quality agreements or audit records for its ethanol suppliers; its quality control unit also lacked the authority and records to oversee manufacturing.

    21 CFR 211.84(d)(2); 21 CFR 211.22

What FDA wants

FDA asks Seatex to reply in writing within 15 working days describing what it has done to fix the violations and prevent recurrence, or to explain any delay and give a completion schedule. FDA also asks the company to say whether it plans to resume drug manufacturing and to notify the agency before doing so.

Who should pay attention

  • brands and retailers selling store-brand hand sanitizer made by contract manufacturers
  • companies that buy OTC topical drug products from this facility
  • quality teams that accept supplier certificates of analysis for glycerin or ethanol

This is a summary. Read the original letter on fda.gov.

Seatex, LLC's FDA history

  1. Seatex, LLC

    Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.

    High risk

Full company page

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium